Supplemental Cash Flow Disclosures (Tables)

12 Months Ended

Jan. 31, 2026

January 31,

2026

January 31,

2025

January 31,

2024

Supplemental disclosures:

Interest paid

6,660

31,817

–

Non-cash investing and financing activities:

Common shares issued for settlement of amounts due to related parties and accounts payable

1,349,937

19,688

–

Common shares of MedMelior issued for settlement of amounts due to related parties

–

284,000

–

Brokers’ warrants granted as issue costs for convertible debentures

–

14,606

–

Common shares and share purchase warrants issued for conversion of debentures and accrued interest

619,691

702,180

–

Brokers’ warrants granted as share issue costs

–

45,371